saccharomyces boulardii
What does the research say about saccharomyces boulardii?
9 health outcomes synthesisedSaccharomyces boulardii is a probiotic yeast studied primarily for its effects on digestive health outcomes. Across 9 distinct health outcomes, the strongest evidence is for reducing diarrhea (9 studies), where moderate effect sizes were observed in clinical populations such as patients on antibiotics or undergoing radiotherapy. Doses ranged from 250 mg/day to 500 mg four times daily, with most studies lasting around 14 days.
Strongest evidence: The most robust research supports Saccharomyces boulardii for reduced diarrhea, with 9 out of 9 studies showing benefit (moderate effect size, high evidence strength), primarily in clinical populations such as patients with H. pylori infection or those on antibiotics. For reduced diarrhea rate (10 studies, moderate evidence), 8 of 10 studies were positive, with doses of 250–500 mg/day commonly used. In H. pylori eradication, 5 of 8 studies reported benefit (moderate evidence), though effect sizes were mixed and 3 studies were neutral.
Mixed or weaker evidence: Evidence for reduced stool frequency (3 studies, low evidence strength) is promising but preliminary, with all 3 studies showing moderate benefits in children with acute diarrhea. Outcomes like reduced duration of diarrhea (4 studies, moderate evidence) have mixed results: 3 of 4 studies were beneficial, but a meta-analysis found neutral results, tempering confidence.
Effective dose patterns: When doses were reported, a range of 250 mg/day to 500 mg four times daily appeared consistently across multiple outcomes, particularly for diarrhea-related endpoints. In H. pylori-related outcomes, 500–1000 mg/day was noted, though many studies did not specify the dose or form.
Population insights: The majority of research was conducted in clinical populations, especially those with H. pylori infection (affecting 6 of 9 outcomes) and children with acute gastroenteritis. Generalizability to healthy individuals or other contexts is uncertain. Pediatric populations dominated outcomes like reduced stool frequency and diarrhea duration, while adult clinical populations were more common for H. pylori and constipation.
Notable caveats: Across syntheses, a recurring caveat is that the clinical literature is subject to publication bias (null results are less likely to be published). Many studies lacked consistent reporting of dose or form, limiting practical application. Treatment durations were often short (14 days), and longer-term effects are not well studied. For several outcomes, the evidence base is small (only 3–4 studies), making conclusions preliminary.
Frequently asked
What is Saccharomyces boulardii good for according to research?
Research shows S. boulardii is most consistently studied for reducing diarrhea, especially in clinical populations such as patients on antibiotics, undergoing radiotherapy, or with H. pylori infection (9 studies, high evidence). It also shows moderate evidence for improving H. pylori eradication rates and reducing abdominal pain.What dose of Saccharomyces boulardii is typically used in studies?
In studies on diarrhea, doses ranged from 250 mg/day to 500 mg four times daily. For H. pylori-related outcomes, doses of 500–1000 mg/day were reported, though many studies did not specify the dose or supplement form, limiting dose-response conclusions.Who benefits most from Saccharomyces boulardii?
Most studies focused on clinical populations, including patients with H. pylori infection, children with acute gastroenteritis, and hospitalized patients on antibiotics. Benefits in healthy individuals without specific digestive conditions are not well studied, so generalizability is uncertain.Are there caveats or limitations in the research on Saccharomyces boulardii?
Yes. The literature is subject to publication bias (null-result studies are less likely to be published). Many studies did not consistently report dose or duration, and treatment periods were often short (14 days). Several outcomes are based on small evidence bases (only 3–4 studies), making conclusions preliminary.Does Saccharomyces boulardii help with H. pylori eradication?
Moderate evidence from 8 studies suggests S. boulardii may improve H. pylori eradication rates when used as an adjunct to standard therapy, with 5 studies showing benefit and 3 showing neutral results. Effect sizes were mixed, and the improvement in eradication rates was roughly 10–14 percentage points in meta-analyses.Does Saccharomyces boulardii reduce constipation?
Three meta-analyses (moderate evidence) reported large beneficial effects on reducing constipation in patients with H. pylori infection. However, all studies were in this specific population, so benefit for other causes of constipation is uncertain. Doses were not consistently reported.
- High evidenceReduced Diarrhea
- Moderate evidenceReduced Diarrhea Rate
- Moderate evidenceImproved H Pylori Eradication Rates
- Moderate evidenceReduced Abdominal Pain
- Moderate evidenceIncreased Helicobacter pylori Eradication Rate
- Moderate evidenceReduced Duration of Diarrhea
- Moderate evidenceReduced Abdominal Distension
- Moderate evidenceReduced Constipation
- Low evidenceReduced Stool Frequency
- Improved Stool Consistency